Senior Clinical Research Associate (Sr CRA) at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, BiotechnologyIndustries

Skills

Key technologies and capabilities for this role

Clinical ResearchICH/GCPSOPsProtocol DevelopmentStudy ManagementVendor ManagementData ReviewTimeline DevelopmentBudget Management

Questions & Answers

Common questions about this position

What is the work arrangement or location policy for this role?

The position is hybrid, typically requiring on-site presence at least 3 days per week.

What is the salary for this Senior CRA position?

This information is not specified in the job description.

What are the required skills or qualifications for this role?

This information is not specified in the job description.

What is the company culture or team environment like?

The role involves working closely with a cross-functional team and as an integral member of a multifunctional team to execute clinical studies according to Corcept’s SOPs, ICH/GCP, and program goals.

What makes a strong candidate for this Senior CRA position?

Strong candidates will have experience independently managing clinical studies or handling significant responsibilities on larger studies, along with skills in study management, vendor oversight, protocol development, and cross-functional teamwork.

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free